|
|
View Clinical Trial (Medical Research Study)
|
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma - NCT00315731-19104 (Clinical Trial 140969)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy140969.aspx
|
** Please review additional "Nearby Studies" on right ----->
This is an archived study that is no longer available, if you
would like to find active studies please
search our studies.
|
|
 |
 |
|
| City: |
|
Philadelphia |
|
State:
|
|
PA |
| Zip Code: |
|
19104 |
| Conditions: |
|
Non-Hodgkin's Lymphoma - Follicular Lymphoma - Diffuse Large Cell Lymphoma |
| Purpose: |
|
Patients will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I 131
Tositumomab. Pharmacokinetic data for the primary endpoint analysis will be derived from
testing done on blood samples drawn at 12 timepoints over the first 7 days following
administration of the dosimetric dose. Whole body gamma camera images will be obtained on
six days following the dosimetric dose. Organ and tumor dosimetry data will be generated
from gamma camera counts of specific organs and tumor. All scans will be examined by an
independent review panel to evaluate biodistribution of the radionuclide.
Using the dosimetric data from three of the six imaging time points and the patient's
weight, a patient-specific activity (mCi) of Iodine-131 will be calculated to deliver the
desired total body dose of radiation (75 cGy). Patients will receive an infusion of
unlabeled Tositumomab (450 mg) immediately followed by an infusion of the patient specific
dose of tellurium-derived Iodine I 131 Tositumomab (35 mg) to deliver a total body dose
(TBD) of 75 cGy. Patients will be followed closely obtaining safety information during the
post-treatment period, and for response and safety at 3,6,and 12 months during the first
year, annually thereafter up to five years, and annually for additional safety and outcomes
information up to 10 years.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion criteria:
- At least 18 years of age.
- A histologically confirmed diagnosis of: Follicular lymphoma, Grade 1, 2, or 3, or
diffuse large cell lymphoma concurrent with or following the diagnosis of follicular
lymphoma (WHO/REAL classification).International Working Formulation histological
equivalents include:
Follicular, small-cleaved; Follicular, mixed small-cleaved and large-cell; Follicular
large-cell; or Transformed diffuse large cell lymphoma following or concurrent with a
diagnosis of follicular lymphoma.
- Stage III or IV disease at the time of study entry.
- Previously untreated or recurrent lymphoma after no more than four prior qualifying
therapy regimens. Qualifying chemotherapy can be found in Section 13.1, Appendix A.
Steroids alone, as treatment for lymphoma, do not constitute a treatment regimen
- Performance status of at least 70% on the Karnofsky Performance Scale and an
anticipated survival of at least three months. The Karnofsky Performance Scale can be
found in Section 13.2, Appendix B.
- Bi-dimensionally measurable disease with at least one lesion measuring ≥2.0 cm x 2.0
cm (≥4.0 cm2) by CT scan
- Absolute B lymphocyte count (as determined by CD19 reactivity) of 30 to 350 cell/mm3
within 21 days prior to study enrollment
- Absolute neutrophil count ≥1500 cells/mm3; platelet count ≥150,000/mm3; and
hemoglobin ≥10 g/dL within 21 days prior to study enrollment. Blood products and/or
growth factors should not have been taken within 4 weeks prior to blood draw
- Adequate renal function (defined as serum creatinine <1.5 x upper limit of
normal(ULN)) and hepatic function (defined as total bilirubin <1.5 x ULN and
aspartate transaminase (AST) <5 x ULN) within 21 days of study enrollment
- Human anti-murine antibody (HAMA) negative within 21 days prior to study enrollment
- Signed IRB approved consent form prior to any study-specific procedures being
implemented
- Follicular lymphoma (i.e., Grade 1,2, or 3), or diffuse large cell lymphoma
concurrent with or following the diagnosis of follicular lymphoma, including
follicular small cleaved, follicular mixed small-cleaved & large cell; follicular
large-cell; or transformed diffuse large cell lymphoma following or concurrent with a
diagnosis of follicular lymphoma.
- KPS>/=70%.
- Bidimensionally measureable disease with at least one lesion >/= 2.0 cm x 2.0 cm by
CT scan.
- platelet count>/=150,000/mm3; and hemoglobin =10 g/dl within 21 days prior to study
enrollment. Note: Blood products and/or growth factors should not have been taken
within 4 weeks prior to blood draw.
Exclusion criteria:
- Greater than 25% of the intratrabecular marrow space involved by lymphoma in bone
marrow biopsy specimens as assessed microscopically within 90 days of study
enrollment. A unilateral bone marrow biopsy is adequate. The marrow core should be
≥2.0 cm in length. The procedure for bone marrow biopsy analysis of marrow
involvement is found in Section 13.3, Appendix C.
- Prior chemotherapy, biologic therapy, steroids, or radiation therapy as treatment for
NHL within 28 days prior to study enrollment. Subjects receiving low doses of
steroids for non-neoplastic disease may enter this study. ("Low dose steroids" is
defined as ≤10 mg of prednisone or equivalent per day.)
- Prior rituximab therapy within 120 days prior to study enrollment.
- Prior radioimmunotherapy
- Prior splenectomy
- Splenomegaly defined as spleen mass greater than 700 grams, where splenic mass is
defined as: Spleen mass = π (X x Y x Z) / 6 Where X and Y are the greatest
perpendicular diameters in cm on any single computerized axial tomography (CT) scan
slice, and Z is the number of CT scan slices upon which the spleen is visible times
the slice thickness in cm
- Bulky disease as defined as any unidimensional measurement of lymphomatous mass
exceeding 7 cm.
- Prior malignancy other than lymphoma, except for adequately treated skin cancer, in
situ cervical cancer, or other cancer for which the subject has a generally accepted
risk of recurrence less than 20%.
- Central nervous system involvement by lymphoma.
- Evidence of active infection requiring IV antibiotics at the time of study
enrollment.
- Known human immunodeficiency virus (HIV) infection.
- New York Heart Association Class III or IV heart disease or other serious illness
that would preclude evaluation. Criteria can be found in Section 13.4, Appendix D.
- Active obstructive hydronephrosis.
- Evidence of clinically significant ascites or pleural effusion observed on screening
physical exam or baseline CT scan.
- Prior myeloablative therapy.
- History of failed stem cell collection.
- Pregnant or nursing patients. Subjects of childbearing potential must have a negative
serum pregnancy test within 21 days of study enrollment. Males and females of
childbearing age must agree to use effective contraception for up to 12 months
following the radioimmunotherapy.
- Greater than 25% of the intratrabecular marrow space involved by lymphoma in bone
marrow biopsy specimens as assessed microscopically within 90 days of study
enrollment.
- Prior chemotherapy, biologic therapy, steroids, or radiation therapy as treatment for
their NHL within 28 days prior to study enrollment.
- Bulky disease as defined as any unidimensional measurement of lymphomatous mass
exceeding 7 cm.
- Prior malignancy other than lymphoma, except for adequately treated skin cancer, in
situ cervical cancer, or other cancer for which the patient has a generally accepted
risk of recurrence less than 20%.
- CNS involvement by lymphoma.
- Active infection requiring IV antibiotics at study enrollment.
- Active obstructive hydronephrosis.
- Evidence of clinically significant ascites or pleural effusion observed on screening
physical exam or baseline CAT scan. |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|